Cell line/type | Umbilical cord blood stem cells |
---|---|
Species | Human |
Animal free | Yes |
Product | Modified stemline II medium Seet et al. 2009 |
Seet, L. F., Teng, E., Lai, Y. S., Laning, J., Kraus, M., Wnendt, S., ... & Chan, S. L. (2009). Valproic acid enhances the engraftability of human umbilical cord blood hematopoietic stem cells expanded under serumāfree conditions. European journal of haematology, 82(2), 124-132. In this study, the effect of VPA was tested in conjunction with the selective amplification technology developed by Viacell Inc. Stem cells enriched from frozen cord blood were cultured for 7 d, subjected to reselection and grown in fresh medium for a further 7 d. Treatment with VPA resulted in an average two-fold higher expansion of CD45(+)34(+) cells compared with control. Furthermore, VPA-treatment induced higher numbers of CD45(+)34(+) cells to reside in the S phase than control cultured cells and resulted in a 2.5-fold upregulation in HOXB4 expression. Importantly, VPA-treated cells reconstituted hematopoiesis in non-obese diabetic/severe combined immunodeficient mice with a six-fold higher efficiency than control cells. Collectively, the results indicate that VPA, already used clinically for neurologic disorder treatment, is a useful additive for the ex vivo culture of hematopoietic stem/progenitor cells to enhance engraftment efficiency. Enriched human cord blood HSCs were cultured in Stemline II medium supplemented with different components as specified in the Materials and methods, under the heading; Selective amplification. https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1600-0609.2008.01169.x |
|
Source | Literature - modified commercial product |
Chemically defined > Unspecified | Yes |